Key Insights

Highlights

Treatment Research

2 treatments under study, led by 2115gpc3car T Cells

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT07148050Phase 1Recruiting

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

NCT06198296Phase 1Recruiting

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Showing all 2 trials

Research Network

Common Treatments

  • 2115gpc3car T Cells1
  • Sccargpc3xil1521 Car T Cells1

Active Sponsors

  • Seattle Children's Hospital1
  • Baylor College of Medicine1
  • Center for Cell and Gene Therapy, Baylor College of Medicine1

Top Investigators

Related Conditions

  • Malignant Rhabdoid Tumor2
  • Rhabdomyosarcoma2
  • Wilms Tumor2
  • Hepatoblastoma2
  • Hepatocellular Carcinoma2

Activity Timeline